Puma Biotechnology | PBYI - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
Amgen USD 1.51B 2.41B 2025-12
Biogen USD 377.7M 433.7M 2026-03
BioMarin Pharmaceutical USD 141.2M 168.36M 2026-03
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Exelixis USD 267.69M 15M 2026-03
Gilead Sciences USD 2.08B 1.56B 2025-12
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 343.6M 46.34M 2026-03
MacroGenics USD -36.77M 21.84M 2026-03
Moderna USD -799M 612M 2025-12
Novartis USD 3.84B 802M 2026-03
Pfizer USD 5.18B 6.82B 2026-03
PTC Therapeutics USD -2.46M 136.62M 2026-03
Puma Biotechnology USD 20.61M 24.76M 2024-09
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sangamo BioSciences USD -36.05M 12.94M 2024-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Takeda JPY -52.48B 186.34B 2026-03
TG Therapeutics USD 20.36M 24.73M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03